<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Strategies for Engineered Negligible Senescence - Wikipedia</title>
<script>document.documentElement.className = document.documentElement.className.replace( /(^|\s)client-nojs(\s|$)/, "$1client-js$2" );</script>
<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Strategies_for_Engineered_Negligible_Senescence","wgTitle":"Strategies for Engineered Negligible Senescence","wgCurRevisionId":739665012,"wgRevisionId":739665012,"wgArticleId":1364342,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["CS1 maint: Explicit use of et al.","Pages using ISBN magic links","Pages using PMID magic links","All articles with unsourced statements","Articles with unsourced statements from September 2016","Wikipedia articles needing clarification from April 2016","1999 introductions","Ageing","Immortality","Regenerative biomedicine","Biomedical engineering","Emerging technologies","Gerontology","Life extension","Gene therapy"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Strategies_for_Engineered_Negligible_Senescence","wgRelevantArticleId":1364342,"wgRequestId":"WE4yBgpAADgAAaED9mIAAACC","wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgPreferredVariant":"en","wgMFDisplayWikibaseDescriptions":{"search":true,"nearby":true,"watchlist":true,"tagline":false},"wgRelatedArticles":null,"wgRelatedArticlesUseCirrusSearch":true,"wgRelatedArticlesOnlyUseCirrusSearch":false,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgCentralNoticeCookiesToDelete":[],"wgCentralNoticeCategoriesUsingLegacy":["Fundraising","fundraising"],"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgWikibaseItemId":"Q523483","wgCentralAuthMobileDomain":false,"wgVisualEditorToolbarScrollOffset":0,"wgEditSubmitButtonLabelPublish":false});mw.loader.state({"ext.globalCssJs.user.styles":"ready","ext.globalCssJs.site.styles":"ready","site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","user.tokens":"loading","ext.cite.styles":"ready","wikibase.client.init":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","ext.wikimediaBadges":"ready","mediawiki.legacy.shared":"ready","mediawiki.legacy.commonPrint":"ready","mediawiki.sectionAnchor":"ready","mediawiki.skinning.interface":"ready","skins.vector.styles":"ready","ext.globalCssJs.user":"ready","ext.globalCssJs.site":"ready"});mw.loader.implement("user.options@0j3lz3q",function($,jQuery,require,module){mw.user.options.set({"variant":"en"});});mw.loader.implement("user.tokens@1dqfd7l",function ( $, jQuery, require, module ) {
mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});/*@nomin*/;

});mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","site","mediawiki.page.startup","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.legacy.wikibits","mediawiki.searchSuggest","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.watchlist-notice","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.extra-toolbar-buttons","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.centralauth.centralautologin","mmv.head","mmv.bootstrap.autostart","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.navigationTiming","ext.uls.eventlogger","ext.uls.init","ext.uls.interface","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp","skins.vector.js"]);});</script>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector"/>
<script async="" src="/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector"></script>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?debug=false&amp;lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=vector"/>
<meta name="generator" content="MediaWiki 1.29.0-wmf.5"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Strategies_for_Engineered_Negligible_Senescence"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Strategies_for_Engineered_Negligible_Senescence"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Strategies_for_Engineered_Negligible_Senescence rootpage-Strategies_for_Engineered_Negligible_Senescence skin-vector action-view">		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Strategies for Engineered Negligible Senescence</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><script>function mfTempOpenSection(id){var block=document.getElementById("mf-section-"+id);block.className+=" open-block";block.previousSibling.className+=" open-block";}</script><p><b>Strategies for Engineered Negligible Senescence</b> (<b>SENS</b>) is the term coined by British biogerontologist <a href="/wiki/Aubrey_de_Grey" title="Aubrey de Grey">Aubrey de Grey</a> for the diverse range of <a href="/wiki/Regenerative_medicine" title="Regenerative medicine">regenerative medical</a> therapies, either planned or currently in development,<sup id="cite_ref-1" class="reference"><a href="#cite_note-1">[1]</a></sup> for the periodical repair of all age-related damage to human tissue with the ultimate purpose of maintaining a state of <a href="/wiki/Negligible_senescence" title="Negligible senescence">negligible senescence</a> in the patient, thereby postponing <a href="/wiki/Age-associated_disease" class="mw-redirect" title="Age-associated disease">age-associated disease</a> for as long as the therapies are reapplied.<sup id="cite_ref-EndingAging_2-0" class="reference"><a href="#cite_note-EndingAging-2">[2]</a></sup></p>
<p>The term "<a href="/wiki/Negligible_senescence" title="Negligible senescence">negligible senescence</a>" was first used in the early 1990s by professor <a href="/wiki/Caleb_Finch" title="Caleb Finch">Caleb Finch</a> to describe organisms such as <a href="/wiki/Lobsters" class="mw-redirect" title="Lobsters">lobsters</a> and <a href="/wiki/Hydra_(genus)" title="Hydra (genus)">hydras</a>, which do not show symptoms of aging. The term "engineered negligible senescence" first appeared in print in <a href="/wiki/Aubrey_de_Grey" title="Aubrey de Grey">Aubrey de Grey</a>'s 1999 book <i>The Mitochondrial Free Radical Theory of Aging</i>,<sup id="cite_ref-isbn1587061554_3-0" class="reference"><a href="#cite_note-isbn1587061554-3">[3]</a></sup> and was later prefaced with the term "strategies" in the article <i>Time to Talk SENS: Critiquing the Immutability of Human Aging</i><sup id="cite_ref-pmid11976218_4-0" class="reference"><a href="#cite_note-pmid11976218-4">[4]</a></sup> De Grey called SENS a "goal-directed rather than curiosity-driven"<sup id="cite_ref-5" class="reference"><a href="#cite_note-5">[5]</a></sup> approach to the science of aging, and "an effort to expand regenerative medicine into the territory of aging".<sup id="cite_ref-6" class="reference"><a href="#cite_note-6">[6]</a></sup> To this end, SENS identifies seven categories of aging "damage" and a specific regenerative medical proposal for treating each.</p>
<p>While many <a href="/wiki/Biogerontology" class="mw-redirect" title="Biogerontology">biogerontologists</a> find it "worthy of discussion"<sup id="cite_ref-PontinJuly112006_7-0" class="reference"><a href="#cite_note-PontinJuly112006-7">[7]</a></sup><sup id="cite_ref-Invincible_Man_8-0" class="reference"><a href="#cite_note-Invincible_Man-8">[8]</a></sup> and SENS conferences feature important research in the field,<sup id="cite_ref-SENS4Abstracts_9-0" class="reference"><a href="#cite_note-SENS4Abstracts-9">[9]</a></sup><sup id="cite_ref-10" class="reference"><a href="#cite_note-10">[10]</a></sup> some contend that the ultimate goals of de Grey's programme are too speculative given the current state of technology, referring to it as "fantasy rather than science".<sup id="cite_ref-EMBOSENS_11-0" class="reference"><a href="#cite_note-EMBOSENS-11">[11]</a></sup><sup id="cite_ref-Holliday_12-0" class="reference"><a href="#cite_note-Holliday-12">[12]</a></sup></p>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Framework"><span class="tocnumber">1</span> <span class="toctext">Framework</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Types_of_aging_damage_and_treatment_schemes"><span class="tocnumber">2</span> <span class="toctext">Types of aging damage and treatment schemes</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Nuclear_mutations.2Fepimutations.E2.80.94OncoSENS"><span class="tocnumber">2.1</span> <span class="toctext">Nuclear mutations/epimutations—OncoSENS</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Mitochondrial_mutations.E2.80.94MitoSENS"><span class="tocnumber">2.2</span> <span class="toctext">Mitochondrial mutations—MitoSENS</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Intracellular_junk.E2.80.94LysoSENS"><span class="tocnumber">2.3</span> <span class="toctext">Intracellular junk—LysoSENS</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Extracellular_junk.E2.80.94AmyloSENS"><span class="tocnumber">2.4</span> <span class="toctext">Extracellular junk—AmyloSENS</span></a></li>
<li class="toclevel-2 tocsection-7"><a href="#Cell_loss_and_atrophy.E2.80.94RepleniSENS"><span class="tocnumber">2.5</span> <span class="toctext">Cell loss and atrophy—RepleniSENS</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#Cell_senescence.E2.80.94ApoptoSENS"><span class="tocnumber">2.6</span> <span class="toctext">Cell senescence—ApoptoSENS</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Extracellular_crosslinks.E2.80.94GlycoSENS"><span class="tocnumber">2.7</span> <span class="toctext">Extracellular crosslinks—GlycoSENS</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-10"><a href="#Scientific_controversy"><span class="tocnumber">3</span> <span class="toctext">Scientific controversy</span></a>
<ul>
<li class="toclevel-2 tocsection-11"><a href="#Technology_Review_controversy"><span class="tocnumber">3.1</span> <span class="toctext"><i>Technology Review</i> controversy</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#Social_and_economic_implications"><span class="tocnumber">4</span> <span class="toctext">Social and economic implications</span></a></li>
<li class="toclevel-1 tocsection-13"><a href="#SENS_meetings"><span class="tocnumber">5</span> <span class="toctext">SENS meetings</span></a></li>
<li class="toclevel-1 tocsection-14"><a href="#SENS_Research_Foundation"><span class="tocnumber">6</span> <span class="toctext">SENS Research Foundation</span></a></li>
<li class="toclevel-1 tocsection-15"><a href="#See_also"><span class="tocnumber">7</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1 tocsection-16"><a href="#References"><span class="tocnumber">8</span> <span class="toctext">References</span></a>
<ul>
<li class="toclevel-2 tocsection-17"><a href="#Footnotes"><span class="tocnumber">8.1</span> <span class="toctext">Footnotes</span></a></li>
<li class="toclevel-2 tocsection-18"><a href="#Bibliography"><span class="tocnumber">8.2</span> <span class="toctext">Bibliography</span></a></li>
</ul>
</li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Framework">Framework</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=1" title="Edit section: Framework">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:302px;"><a href="/wiki/File:Aging_treatment_approaches.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/a/a8/Aging_treatment_approaches.jpg/300px-Aging_treatment_approaches.jpg" width="300" height="110" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/a/a8/Aging_treatment_approaches.jpg/450px-Aging_treatment_approaches.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/a/a8/Aging_treatment_approaches.jpg/600px-Aging_treatment_approaches.jpg 2x" data-file-width="1167" data-file-height="426" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Aging_treatment_approaches.jpg" class="internal" title="Enlarge"></a></div>
The arrows with flat heads are a notation meaning "inhibits," used in the literature of gene expression and gene regulation.</div>
</div>
</div>
<p>The ultimate objective of SENS is the eventual elimination of age-related diseases and infirmity by repeatedly reducing the state of senescence in the organism. The SENS project consists in implementing a series of periodic medical interventions designed to repair, prevent or render irrelevant all the types of molecular and cellular damage that cause age-related pathology and degeneration, in order to avoid debilitation and death from age-related causes.<sup id="cite_ref-EndingAging_2-1" class="reference"><a href="#cite_note-EndingAging-2">[2]</a></sup></p>
<p>De Grey defines aging as "the set of accumulated side effects from metabolism that eventually kills us", and, more specifically, as follows: "a collection of cumulative changes to the <a href="/wiki/Molecule" title="Molecule">molecular</a> and <a href="/wiki/Cell_(biology)" title="Cell (biology)">cellular</a> structure of an <a href="/wiki/Adult" title="Adult">adult</a> <a href="/wiki/Organism" title="Organism">organism</a>, which result in essential <a href="/wiki/Metabolism" title="Metabolism">metabolic</a> processes, but which also, once they progress far enough, increasingly disrupt metabolism, resulting in <a href="/wiki/Pathology" title="Pathology">pathology</a> and death."<sup id="cite_ref-pmid12844502_13-0" class="reference"><a href="#cite_note-pmid12844502-13">[13]</a></sup> He adds: "<a href="/wiki/Geriatrics" title="Geriatrics">geriatrics</a> is the attempt to stop damage from causing pathology; traditional <a href="/wiki/Gerontology" title="Gerontology">gerontology</a> is the attempt to stop <a href="/wiki/Metabolism" title="Metabolism">metabolism</a> from causing damage; and the SENS (engineering) approach is to eliminate the damage periodically, so keeping its abundance below the level that causes any pathology." The SENS approach to biomedical <a href="/wiki/Gerontology" title="Gerontology">gerontology</a> is thus distinctive because of its emphasis on tissue rejuvenation rather than attempting to slow the aging process.</p>
<p>By enumerating the various differences between young and old tissue identified by the science of <a href="/wiki/Biogerontology" class="mw-redirect" title="Biogerontology">biogerontology</a>, a 'damage' report was drawn, which in turn formed the basis of the SENS strategy. The results fell into seven main categories of 'damage', seven alterations whose reversal would constitute <a href="/wiki/Negligible_senescence" title="Negligible senescence">negligible senescence</a>:</p>
<ol>
<li>cell loss or atrophy (without replacement),<sup id="cite_ref-pmid11976218_4-1" class="reference"><a href="#cite_note-pmid11976218-4">[4]</a></sup><sup id="cite_ref-pmid12844502_13-1" class="reference"><a href="#cite_note-pmid12844502-13">[13]</a></sup><sup id="cite_ref-14" class="reference"><a href="#cite_note-14">[14]</a></sup></li>
<li><a href="/wiki/Oncology" title="Oncology">oncogenic</a> <a href="/wiki/Cell_nucleus" title="Cell nucleus">nuclear</a> <a href="/wiki/Mutation" title="Mutation">mutations</a> and <a href="/wiki/Epimutation" class="mw-redirect" title="Epimutation">epimutations</a>,<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">[15]</a></sup><sup id="cite_ref-16" class="reference"><a href="#cite_note-16">[16]</a></sup><sup id="cite_ref-pmid17588643_17-0" class="reference"><a href="#cite_note-pmid17588643-17">[17]</a></sup></li>
<li>cell <a href="/wiki/Senescence" title="Senescence">senescence</a> (Death-resistant cells),<sup id="cite_ref-pmid12556198_18-0" class="reference"><a href="#cite_note-pmid12556198-18">[18]</a></sup><sup id="cite_ref-pmid17100587_19-0" class="reference"><a href="#cite_note-pmid17100587-19">[19]</a></sup></li>
<li><a href="/wiki/Mitochondria" class="mw-redirect" title="Mitochondria">mitochondrial</a> mutations,<sup id="cite_ref-20" class="reference"><a href="#cite_note-20">[20]</a></sup><sup id="cite_ref-21" class="reference"><a href="#cite_note-21">[21]</a></sup></li>
<li>Intracellular junk or junk inside cells (<a href="/wiki/Lysosome" title="Lysosome">lysosomal</a> aggregates),<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">[22]</a></sup><sup id="cite_ref-23" class="reference"><a href="#cite_note-23">[23]</a></sup></li>
<li>extracellular junk or junk outside cells (extracellular aggregates),<sup id="cite_ref-pmid12556198_18-1" class="reference"><a href="#cite_note-pmid12556198-18">[18]</a></sup><sup id="cite_ref-pmid17100587_19-1" class="reference"><a href="#cite_note-pmid17100587-19">[19]</a></sup></li>
<li>random extracellular cross-linking.<sup id="cite_ref-pmid12556198_18-2" class="reference"><a href="#cite_note-pmid12556198-18">[18]</a></sup><sup id="cite_ref-pmid17100587_19-2" class="reference"><a href="#cite_note-pmid17100587-19">[19]</a></sup></li>
</ol>
<p>For each of these areas SENS offers at least one strategy, with a research and a clinical component. The clinical component is required because in some of the proposed therapies, feasibility has already been proven, but not completely applied and approved for human trials. These strategies do not presuppose that the underlying metabolic mechanisms of aging be fully understood, only that we take into account the form senescence takes as directly observable to science, and described in scientific literature..</p>
<h2><span class="mw-headline" id="Types_of_aging_damage_and_treatment_schemes">Types of aging damage and treatment schemes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=2" title="Edit section: Types of aging damage and treatment schemes">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Nuclear_mutations.2Fepimutations.E2.80.94OncoSENS">Nuclear mutations/epimutations—OncoSENS</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=3" title="Edit section: Nuclear mutations/epimutations—OncoSENS">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>These are changes to the nuclear DNA (<a href="/wiki/NDNA" class="mw-redirect" title="NDNA">nDNA</a>), or to proteins which bind to the nDNA. Certain mutations can lead to <a href="/wiki/Cancer" title="Cancer">cancer</a>.</p>
<p>This would need to be corrected in order to prevent or <a href="/wiki/Cure_for_cancer" class="mw-redirect" title="Cure for cancer">cure cancer</a>. SENS focuses on a strategy called "whole-body interdiction of lengthening <a href="/wiki/Telomere" title="Telomere">telomeres</a>" (WILT), which would be made possible by periodic <a href="/wiki/Regenerative_medicine" title="Regenerative medicine">regenerative medicine</a> treatments.</p>
<h3><span class="mw-headline" id="Mitochondrial_mutations.E2.80.94MitoSENS">Mitochondrial mutations—MitoSENS</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=4" title="Edit section: Mitochondrial mutations—MitoSENS">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Mitochondria" class="mw-redirect" title="Mitochondria">Mitochondria</a> are components in our <a href="/wiki/Cell_(biology)" title="Cell (biology)">cells</a> that are important for <a href="/wiki/Energy" title="Energy">energy</a> production. Because of the highly <a href="/wiki/Oxidative_stress" title="Oxidative stress">oxidative</a> environment in mitochondria and their lack of the sophisticated repair systems, mitochondrial mutations are believed to be a major cause of progressive cellular degeneration.</p>
<p>This would be corrected by <a href="/wiki/Allotopic_expression" title="Allotopic expression">allotopic expression</a>—copying the <a href="/wiki/DNA" title="DNA">DNA</a> for mitochondria completely within the cellular <a href="/wiki/Cell_nucleus" title="Cell nucleus">nucleus</a>, where it is better protected. De Grey argues that experimental evidence demonstrates that the operation is feasible, however, a 2003 study showed that some mitochondrial proteins are too <a href="/wiki/Hydrophobic" class="mw-redirect" title="Hydrophobic">hydrophobic</a> to survive the transport from the cytoplasm to the mitochondria.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24">[24]</a></sup></p>
<h3><span class="mw-headline" id="Intracellular_junk.E2.80.94LysoSENS">Intracellular junk—LysoSENS</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=5" title="Edit section: Intracellular junk—LysoSENS">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Our cells are constantly breaking down <a href="/wiki/Protein" title="Protein">proteins</a> and other molecules that are no longer useful or which can be harmful. Those molecules which can’t be digested accumulate as junk inside our cells, which is detected in the form of <a href="/wiki/Lipofuscin" title="Lipofuscin">lipofuscin</a> granules. <a href="/wiki/Atherosclerosis" title="Atherosclerosis">Atherosclerosis</a>, <a href="/wiki/Macular_degeneration" title="Macular degeneration">macular degeneration</a>, <a href="/wiki/Liver_spot" title="Liver spot">liver spots</a> on the skin and all kinds of <a href="/wiki/Neurodegenerative_disease" class="mw-redirect" title="Neurodegenerative disease">neurodegenerative diseases</a> (such as <a href="/wiki/Alzheimer%27s" class="mw-redirect" title="Alzheimer's">Alzheimer's</a> disease) are associated with this problem.</p>
<p>Junk inside cells might be removed by adding new <a href="/wiki/Enzymes" class="mw-redirect" title="Enzymes">enzymes</a> to the cell's natural <a href="/wiki/Digestion" title="Digestion">digestion</a> organ, the <a href="/wiki/Lysosome" title="Lysosome">lysosome</a>. These enzymes would be taken from <a href="/wiki/Bacteria" title="Bacteria">bacteria</a>, <a href="/wiki/Mold" title="Mold">molds</a> and other organisms that are known to completely digest animal bodies.</p>
<h3><span class="mw-headline" id="Extracellular_junk.E2.80.94AmyloSENS">Extracellular junk—AmyloSENS</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=6" title="Edit section: Extracellular junk—AmyloSENS">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Harmful junk protein can accumulate outside of our cells. Junk here means useless things accumulated by a body, but which cannot be digested or removed by its processes, such as the amyloid plaques characteristic of <a href="/wiki/Alzheimer%27s_disease" title="Alzheimer's disease">Alzheimer's disease</a> and other <a href="/wiki/Amyloidosis" title="Amyloidosis">amyloidoses</a>.</p>
<p>Junk outside cells might be removed by enhanced <a href="/wiki/Phagocytosis" title="Phagocytosis">phagocytosis</a> (the normal process used by the immune system), and small drugs able to break chemical beta-bonds. The large junk in this class can be removed surgically.</p>
<h3><span class="mw-headline" id="Cell_loss_and_atrophy.E2.80.94RepleniSENS">Cell loss and atrophy—RepleniSENS</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=7" title="Edit section: Cell loss and atrophy—RepleniSENS">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Some of the cells in our bodies cannot be replaced, or can be only replaced very slowly—more slowly than they die. This decrease in cell number affects some of the most important tissues of the body. Muscle cells are lost in <a href="/wiki/Skeletal_muscle" title="Skeletal muscle">skeletal muscles</a> and the heart, causing them to become frailer with age. Loss of neurons in the <a href="/wiki/Substantia_nigra" title="Substantia nigra">substantia nigra</a> causes <a href="/wiki/Parkinson%27s_disease" title="Parkinson's disease">Parkinson's disease</a>, while loss of immune cells impairs the <a href="/wiki/Immune_system" title="Immune system">immune system</a>.</p>
<p>This can be partly corrected by therapies involving <a href="/wiki/Exercise" class="mw-redirect" title="Exercise">exercise</a> and <a href="/wiki/Growth_factor" title="Growth factor">growth factors</a>, but <a href="/wiki/Stem_cell_therapy" class="mw-redirect" title="Stem cell therapy">stem cell therapy</a>, <a href="/wiki/Regenerative_medicine" title="Regenerative medicine">regenerative medicine</a> and <a href="/wiki/Tissue_engineering" title="Tissue engineering">tissue engineering</a> are almost certainly required for any more than just partial replacement of lost cells.</p>
<h3><span class="mw-headline" id="Cell_senescence.E2.80.94ApoptoSENS">Cell senescence—ApoptoSENS</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=8" title="Edit section: Cell senescence—ApoptoSENS">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p><a href="/wiki/Cellular_senescence#Cellular_senescence" title="Cellular senescence">Senescence</a> is a phenomenon where the cells are no longer able to divide, but also do not die and let others divide. They may also do other harmful things, like secreting proteins. Degeneration of <a href="/wiki/Joint" title="Joint">joints</a>, immune senescence, accumulation of <a href="/wiki/Visceral_fat" class="mw-redirect" title="Visceral fat">visceral fat</a> and <a href="/wiki/Diabetes_mellitus_type_2" title="Diabetes mellitus type 2">type 2 diabetes</a> are caused by this. Cells sometimes enter a state of resistance to signals sent, as part of a process called <a href="/wiki/Apoptosis" title="Apoptosis">apoptosis</a>, to instruct cells to destroy themselves.</p>
<p>Cells in this state could be eliminated by forcing them to apoptose (via <a href="/wiki/Suicide_gene" title="Suicide gene">suicide genes</a>, <a href="/wiki/Vaccine" title="Vaccine">vaccines</a>, or recently discovered <a href="/wiki/Senolytics" class="mw-redirect" title="Senolytics">senolytic agents</a>), and healthy cells would multiply to replace them.</p>
<h3><span class="mw-headline" id="Extracellular_crosslinks.E2.80.94GlycoSENS">Extracellular crosslinks—GlycoSENS</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=9" title="Edit section: Extracellular crosslinks—GlycoSENS">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Cells are held together by special linking proteins. When too many <a href="/wiki/Cross-links" class="mw-redirect" title="Cross-links">cross-links</a> form between cells in a <a href="/wiki/Biological_tissue" class="mw-redirect" title="Biological tissue">tissue</a>, the tissue can lose its elasticity and cause problems including arteriosclerosis, presbyopia and weakened skin texture. These are chemical bonds between structures that are part of the body, but not within a <a href="/wiki/Cell_(biology)" title="Cell (biology)">cell</a>. In senescent people many of these become brittle and weak.</p>
<p>SENS proposes to further develop small-molecular drugs and <a href="/wiki/Enzyme" title="Enzyme">enzymes</a> to break links caused by sugar-bonding, known as <a href="/wiki/Advanced_glycation_endproduct" class="mw-redirect" title="Advanced glycation endproduct">advanced glycation endproducts</a>, and other common forms of chemical linking.</p>
<h2><span class="mw-headline" id="Scientific_controversy">Scientific controversy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=10" title="Edit section: Scientific controversy">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>While some fields mentioned as branches of SENS are broadly supported by the medical research community, e.g., <a href="/wiki/Stem_cell_research" class="mw-redirect" title="Stem cell research">stem cell research</a> (RepleniSENS), <a href="/wiki/Alzheimer%27s_disease_clinical_research" class="mw-redirect" title="Alzheimer's disease clinical research">anti-Alzheimers research</a> (AmyloSENS) and <a href="/wiki/Oncogenomics" title="Oncogenomics">oncogenomics</a> (OncoSENS), the SENS programme as a whole has been a highly controversial proposal, with many critics arguing that the SENS agenda is fanciful and the highly complicated biomedical phenomena involved in the aging process contain too many unknowns for SENS to be fully implementable in the foreseeable future. Cancer may well deserve special attention as an <a href="/wiki/Aging-associated_diseases" title="Aging-associated diseases">aging-associated disease</a> (OncoSENS), but the SENS claim that nuclear DNA damage only matters for aging because of cancer has been challenged in the literature<sup id="cite_ref-25" class="reference"><a href="#cite_note-25">[25]</a></sup> as well as by material in the article <a href="/wiki/DNA_damage_theory_of_aging" title="DNA damage theory of aging">DNA damage theory of aging</a>.</p>
<p>In November 2005, 28 biogerontologists published a statement of criticism in <i><a href="/wiki/EMBO_Journal" class="mw-redirect" title="EMBO Journal">EMBO reports</a></i>, "Science fact and the SENS agenda: what can we reasonably expect from ageing research?,"<sup id="cite_ref-pmid16264422_26-0" class="reference"><a href="#cite_note-pmid16264422-26">[26]</a></sup> arguing "each one of the specific proposals that comprise the SENS agenda is, at our present stage of ignorance, exceptionally optimistic,"<sup id="cite_ref-pmid16264422_26-1" class="reference"><a href="#cite_note-pmid16264422-26">[26]</a></sup> and that some of the specific proposals "will take decades of hard work [to be medically integrated], if [they] ever prove to be useful."<sup id="cite_ref-pmid16264422_26-2" class="reference"><a href="#cite_note-pmid16264422-26">[26]</a></sup> The researchers argue that while there is "a rationale for thinking that we might eventually learn how to postpone human illnesses to an important degree,"<sup id="cite_ref-pmid16264422_26-3" class="reference"><a href="#cite_note-pmid16264422-26">[26]</a></sup> increased basic research, rather than the goal-directed approach of SENS, is presently the scientifically appropriate goal. This article was written in response to a July 2005 <i>EMBO reports</i> article previously published by de Grey<sup id="cite_ref-27" class="reference"><a href="#cite_note-27">[27]</a></sup> and a response from de Grey was published in the same November issue.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28">[28]</a></sup> De Grey summarizes these events in "The biogerontology research community's evolving view of SENS," published on the <a href="/wiki/Methuselah_Foundation" title="Methuselah Foundation">Methuselah Foundation</a> website.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29">[29]</a></sup></p>
<p>In 2012, <a href="/wiki/Colin_Blakemore" title="Colin Blakemore">Colin Blakemore</a> criticised Aubrey de Grey, but not SENS specifically, in a debate hosted at the <a href="/wiki/Oxford_University" class="mw-redirect" title="Oxford University">Oxford University</a> Scientific Society.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (September 2016)">citation needed</span></a></i>]</sup></p>
<p>More recently, biogerontologist <a href="/wiki/Marios_Kyriazis" title="Marios Kyriazis">Marios Kyriazis</a> has sharply criticised the clinical applicability of SENS<sup id="cite_ref-30" class="reference"><a href="#cite_note-30">[30]</a></sup><sup id="cite_ref-31" class="reference"><a href="#cite_note-31">[31]</a></sup> claiming that such therapies, even if developed in the laboratory, would be practically unusable by the general public.<sup id="cite_ref-32" class="reference"><a href="#cite_note-32">[32]</a></sup> De Grey responded to one such criticism.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33">[33]</a></sup></p>
<h3><span class="mw-headline" id="Technology_Review_controversy"><i>Technology Review</i> controversy</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=11" title="Edit section: Technology Review controversy">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In February 2005, <i><a href="/wiki/Technology_Review" class="mw-redirect" title="Technology Review">Technology Review</a></i>, which is owned by the <a href="/wiki/Massachusetts_Institute_of_Technology" title="Massachusetts Institute of Technology">Massachusetts Institute of Technology</a>, published an article by <a href="/wiki/Sherwin_Nuland" class="mw-redirect" title="Sherwin Nuland">Sherwin Nuland</a>, a Clinical Professor of Surgery at <a href="/wiki/Yale_University" title="Yale University">Yale University</a> and the author of "How We Die",<sup id="cite_ref-34" class="reference"><a href="#cite_note-34">[34]</a></sup> that drew a skeptical portrait of SENS, at the time de Grey was a computer associate in the <a rel="nofollow" class="external text" href="https://web.archive.org/web/20100108033304/http://www.gen.cam.ac.uk/Research/flybase.htm">Flybase Facility</a> of the <a rel="nofollow" class="external text" href="http://www.gen.cam.ac.uk/">Department of Genetics</a> at the <a href="/wiki/University_of_Cambridge" title="University of Cambridge">University of Cambridge</a>. The April 2005 issue of <i>Technology Review</i> contained a reply by Aubrey de Grey<sup id="cite_ref-35" class="reference"><a href="#cite_note-35">[35]</a></sup> and numerous comments from readers.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36">[36]</a></sup></p>
<p>During June 2005, <a href="/wiki/David_Gobel" title="David Gobel">David Gobel</a>, CEO and Co-founder of Methuselah Foundation offered Technology Review $20,000 to fund a prize competition to publicly clarify the viability of the SENS approach. In July 2005, Pontin announced a $20,000 prize, funded 50/50 by Methuselah Foundation and MIT Technology Review, open to any molecular biologist, with a record of publication in biogerontology, who could prove that the alleged benefits of SENS were "so wrong that it is unworthy of learned debate."<sup id="cite_ref-37" class="reference"><a href="#cite_note-37">[37]</a></sup> <i>Technology Review</i> received five submissions to its Challenge. In March 2006, <i>Technology Review</i> announced that it had chosen a panel of judges for the Challenge: <a href="/wiki/Rodney_Brooks" title="Rodney Brooks">Rodney Brooks</a>, <a href="/wiki/Anita_Goel" title="Anita Goel">Anita Goel</a>, <a href="/wiki/Nathan_Myhrvold" title="Nathan Myhrvold">Nathan Myhrvold</a>, <a href="/wiki/Vikram_Sheel_Kumar" title="Vikram Sheel Kumar">Vikram Sheel Kumar</a>, and <a href="/wiki/Craig_Venter" title="Craig Venter">Craig Venter</a>.<sup id="cite_ref-38" class="reference"><a href="#cite_note-38">[38]</a></sup> Three of the five submissions met the terms of the prize competition. They were published by <i>Technology Review</i> on June 9, 2006. Accompanying the three submissions were rebuttals by de Grey, and counter-responses to de Grey's rebuttals. On July 11, 2006, <i>Technology Review</i> published the results of the SENS Challenge.<sup id="cite_ref-PontinJuly112006_7-1" class="reference"><a href="#cite_note-PontinJuly112006-7">[7]</a></sup><sup id="cite_ref-39" class="reference"><a href="#cite_note-39">[39]</a></sup></p>
<p>In the end, no one won the $20,000 prize. The judges felt that no submission met the criterion of the challenge and discredited SENS, although they unanimously agreed that one submission, by <a href="/wiki/Preston_Estep" title="Preston Estep">Preston Estep</a> and his colleagues, was the most eloquent. <a href="/wiki/Craig_Venter" title="Craig Venter">Craig Venter</a> succinctly expressed the prevailing opinion: "Estep et al. ... have not demonstrated that SENS is unworthy of discussion, but the proponents of SENS have not made a compelling case for it."<sup id="cite_ref-PontinJuly112006_7-2" class="reference"><a href="#cite_note-PontinJuly112006-7">[7]</a></sup> Summarizing the judges' deliberations, Pontin wrote that SENS is "highly speculative" and that many of its proposals <span class="cleanup-needed-content" style="padding-left:0.1em; padding-right:0.1em; color:#595959; border:1px solid #DDD;">could not be reproduced with the scientific technology of that period.</span><sup class="noprint Inline-Template" style="margin-left:0.1em; white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Please_clarify" title="Wikipedia:Please clarify"><span title="The text near this tag may need clarification or removal of jargon. (April 2016)">clarification needed</span></a></i>]</sup> Myhrvold described SENS as belonging to a kind of "antechamber of science" where they wait until technology and scientific knowledge advance to the point where it can be tested.<sup id="cite_ref-PontinJuly112006_7-3" class="reference"><a href="#cite_note-PontinJuly112006-7">[7]</a></sup><sup id="cite_ref-Invincible_Man_8-1" class="reference"><a href="#cite_note-Invincible_Man-8">[8]</a></sup> In a letter of dissent dated July 11, 2006 in Technology Review, Estep et al. criticized the ruling of the judges.</p>
<h2><span class="mw-headline" id="Social_and_economic_implications">Social and economic implications</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=12" title="Edit section: Social and economic implications">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Of the roughly 150,000 people who die each day across the globe, about two thirds—100,000 per day—die of age-related causes.<sup id="cite_ref-doi10.2202.2F1941-6008.1011_40-0" class="reference"><a href="#cite_note-doi10.2202.2F1941-6008.1011-40">[40]</a></sup> In industrialized nations, the proportion is much higher, reaching 90%.<sup id="cite_ref-doi10.2202.2F1941-6008.1011_40-1" class="reference"><a href="#cite_note-doi10.2202.2F1941-6008.1011-40">[40]</a></sup></p>
<p>De Grey and other scientists in the general field have argued that the costs of a rapidly growing aging population will increase to the degree that the costs of an accelerated pace of aging research are easy to justify in terms of future costs avoided. Olshansky <i>et al.</i> 2006 argue, for example, that the total economic cost of <a href="/wiki/Alzheimer%27s_disease" title="Alzheimer's disease">Alzheimer's disease</a> in the US alone will increase from $80–100 billion today to more than $1 trillion in 2050.<sup id="cite_ref-TheLongevityDividend_41-0" class="reference"><a href="#cite_note-TheLongevityDividend-41">[41]</a></sup> "Consider what is likely to happen if we don't [invest further in aging research]. Take, for instance, the impact of just one age-related disorder, Alzheimer disease (AD). For no other reason than the inevitable shifting demographics, the number of Americans stricken with AD will rise from 4 million today to as many as 16 million by midcentury. This means that more people in the United States will have AD by 2050 than the entire current population of the Netherlands. Globally, AD prevalence is expected to rise to 45 million by 2050, with three of every four patients with AD living in a developing nation. The US economic toll is currently $80–$100 billion, but by 2050 more than $1 trillion will be spent annually on AD and related dementias. The impact of this single disease will be catastrophic, and this is just one example."<sup id="cite_ref-TheLongevityDividend_41-1" class="reference"><a href="#cite_note-TheLongevityDividend-41">[41]</a></sup></p>
<h2><span class="mw-headline" id="SENS_meetings">SENS meetings</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=13" title="Edit section: SENS meetings">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>There have been four SENS <a href="/wiki/Round_table" class="mw-redirect" title="Round table">roundtables</a> and six SENS <a href="/wiki/Academic_conference" title="Academic conference">conferences</a> held.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42">[42]</a></sup><sup id="cite_ref-sens6_43-0" class="reference"><a href="#cite_note-sens6-43">[43]</a></sup> The first SENS roundtable was held in <a href="/wiki/Oakland,_California" title="Oakland, California">Oakland, California</a> on October, 2000,<sup id="cite_ref-44" class="reference"><a href="#cite_note-44">[44]</a></sup> and the last SENS roundtable was held in <a href="/wiki/Bethesda,_Maryland" title="Bethesda, Maryland">Bethesda, Maryland</a> on July, 2004.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45">[45]</a></sup></p>
<p>On March 30–31, 2007 a North American SENS symposium was held in <a href="/wiki/Edmonton,_Alberta" class="mw-redirect" title="Edmonton, Alberta">Edmonton, Alberta</a>, <a href="/wiki/Canada" title="Canada">Canada</a> as the <i>Edmonton Aging Symposium</i>.<sup id="cite_ref-46" class="reference"><a href="#cite_note-46">[46]</a></sup><sup id="cite_ref-47" class="reference"><a href="#cite_note-47">[47]</a></sup> Another SENS-related conference ("Understanding Aging") was held at <a href="/wiki/University_of_California,_Los_Angeles" title="University of California, Los Angeles">UCLA</a> in <a href="/wiki/Los_Angeles" title="Los Angeles">Los Angeles</a>, <a href="/wiki/California" title="California">California</a> on June&#160;27-29, 2008<sup id="cite_ref-48" class="reference"><a href="#cite_note-48">[48]</a></sup></p>
<p>Six SENS conferences have been held at <a href="/wiki/Queens%27_College,_Cambridge" title="Queens' College, Cambridge">Queens' College, Cambridge</a> in <a href="/wiki/England" title="England">England</a>. All the conferences were organized by de Grey and all featured world-class researchers in the field of <a href="/wiki/Gerontology#Biogerontology" title="Gerontology">biogerontology</a>.</p>
<ul>
<li>The first SENS conference was held in September 2003 as the <i>10th Congress of the International Association of Biomedical Gerontology</i><sup id="cite_ref-49" class="reference"><a href="#cite_note-49">[49]</a></sup> with the proceedings published in the <i>Annals of the New York Academy of Sciences</i>.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50">[50]</a></sup></li>
<li>The second SENS conference was held in September 2005 and was simply called <i>Strategies for Engineered Negligible Senescence (SENS), Second Conference</i><sup id="cite_ref-51" class="reference"><a href="#cite_note-51">[51]</a></sup> with the proceedings published in <i><a href="/wiki/Rejuvenation_Research" title="Rejuvenation Research">Rejuvenation Research</a></i>.</li>
<li>The third SENS conference was held in September, 2007.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52">[52]</a></sup></li>
<li>The fourth SENS conference was held September 3–7, 2009.</li>
<li>The fifth was held August 31 - September 4, 2011, like the first four, it was at Queens' College, Cambridge in England, organized by de Grey.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53">[53]</a></sup><sup id="cite_ref-54" class="reference"><a href="#cite_note-54">[54]</a></sup> Videos of the presentations are <a rel="nofollow" class="external text" href="http://www.sens.org/conferences/sens5">available</a>.</li>
<li>The sixth SENS conference (SENS6) was held from September 3–7, 2013.</li>
</ul>
<p>Another meeting was held in August 2014 in Santa Clara, California.<sup id="cite_ref-sens6_43-1" class="reference"><a href="#cite_note-sens6-43">[43]</a></sup></p>
<h2><span class="mw-headline" id="SENS_Research_Foundation">SENS Research Foundation</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=14" title="Edit section: SENS Research Foundation">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div role="note" class="hatnote">Main article: <a href="/wiki/SENS_Research_Foundation" title="SENS Research Foundation">SENS Research Foundation</a></div>
<p>The SENS Research Foundation is a <a href="/wiki/Non-profit_organization" class="mw-redirect" title="Non-profit organization">non-profit organization</a> co-founded by Michael Kope, <a href="/wiki/Aubrey_de_Grey" title="Aubrey de Grey">Aubrey de Grey</a>, Jeff Hall, Sarah Marr and Kevin Perrott, which is based in <a href="/wiki/California" title="California">California</a>, <a href="/wiki/United_States" title="United States">United States</a>. Its activities include SENS-based research programs and <a href="/wiki/Public_relations" title="Public relations">public relations</a> work for the acceptance of and interest in related research.</p>
<p>Before March 2009, the SENS research programme was mainly pursued by the <a href="/wiki/Methuselah_Foundation" title="Methuselah Foundation">Methuselah Foundation</a>, co-founded by Aubrey de Grey and David Gobel. The <a href="/wiki/Methuselah_Foundation" title="Methuselah Foundation">Methuselah Foundation</a> is most notable for establishing the <a href="/wiki/Methuselah_Mouse_Prize" class="mw-redirect" title="Methuselah Mouse Prize">Methuselah Mouse Prize</a>, a monetary prize awarded to researchers who extend the lifespan of mice to unprecedented lengths.<sup id="cite_ref-MFMission_55-0" class="reference"><a href="#cite_note-MFMission-55">[55]</a></sup></p>
<p>For 2013, The SENS Research Foundation has a research budget of approximately $4 million annually, half of it funded by a personal contribution of $13 million of Aubrey de Grey's<sup id="cite_ref-56" class="reference"><a href="#cite_note-56">[56]</a></sup> own wealth, and the other half coming from external donors, with the largest external donor being <a href="/wiki/Peter_Thiel" title="Peter Thiel">Peter Thiel</a>, and another Internet entrepreneur Jason Hope,<sup id="cite_ref-57" class="reference"><a href="#cite_note-57">[57]</a></sup> has recently begun to contribute comparable sums.</p>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=15" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table role="presentation" class="mbox-small plainlinks sistersitebox" style="border:1px solid #aaa;background-color:#f9f9f9">
<tr>
<td class="mbox-image"><a href="/wiki/File:Wikiversity-logo.svg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/9/91/Wikiversity-logo.svg/40px-Wikiversity-logo.svg.png" width="40" height="32" class="noviewer" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/9/91/Wikiversity-logo.svg/60px-Wikiversity-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/9/91/Wikiversity-logo.svg/80px-Wikiversity-logo.svg.png 2x" data-file-width="1000" data-file-height="800" /></a></td>
<td class="mbox-text plainlist">Wikiversity has learning materials about <i><b><a href="https://en.wikiversity.org/wiki/Special:Search/Strategies_for_Engineered_Negligible_Senescence" class="extiw" title="v:Special:Search/Strategies for Engineered Negligible Senescence">Strategies for Engineered Negligible Senescence</a></b></i></td>
</tr>
</table>
<div class="div-col columns column-count column-count-20em" style="-moz-column-count: 20em; -webkit-column-count: 20em; column-count: 20em;">
<ul>
<li><a href="/wiki/Aging" class="mw-redirect" title="Aging">Aging</a></li>
<li><a href="/wiki/Aging-associated_diseases" title="Aging-associated diseases">Aging-associated diseases</a></li>
<li><a href="/wiki/American_Academy_of_Anti-Aging_Medicine" title="American Academy of Anti-Aging Medicine">American Academy of Anti-Aging Medicine</a></li>
<li><a href="/wiki/Biological_immortality" title="Biological immortality">Biological immortality</a></li>
<li><a href="/wiki/DNA_damage_theory_of_aging" title="DNA damage theory of aging">DNA damage theory of aging</a></li>
<li><a href="/wiki/Eternal_youth" title="Eternal youth">Eternal youth</a></li>
<li><a href="/wiki/Genetics_of_aging" title="Genetics of aging">Genetics of aging</a></li>
<li><a href="/wiki/Immortality" title="Immortality">Immortality</a></li>
<li><a href="/wiki/Indefinite_lifespan" title="Indefinite lifespan">Indefinite lifespan</a></li>
<li><a href="/wiki/Longevity" title="Longevity">Longevity</a></li>
<li><a href="/wiki/Maximum_life_span" title="Maximum life span">Maximum life span</a></li>
<li><a href="/wiki/Protoscience" title="Protoscience">Protoscience</a></li>
<li><a href="/wiki/Rejuvenation_Research" title="Rejuvenation Research">Rejuvenation Research</a></li>
<li><a href="/wiki/Senolytics" class="mw-redirect" title="Senolytics">Senolytics</a></li>
<li><a href="/wiki/Geroprotector" title="Geroprotector">Geroprotector</a></li>
<li><a href="/wiki/Timeline_of_senescence_research" title="Timeline of senescence research">Timeline of senescence research</a></li>
</ul>
</div>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=16" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="Footnotes">Footnotes</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=17" title="Edit section: Footnotes">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-1">^</a></b></span> <span class="reference-text">Research Themes (February 4, 2013). "<a rel="nofollow" class="external free" href="http://www.sens.org/research/introduction-to-sens-research">http://www.sens.org/research/introduction-to-sens-research</a>". <i>SENS Research Foundation website</i></span></li>
<li id="cite_note-EndingAging-2"><span class="mw-cite-backlink">^ <a href="#cite_ref-EndingAging_2-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-EndingAging_2-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">de Grey, Aubrey; Rae, Michael (September 2007). <i>Ending Aging: The Rejuvenation Breakthroughs that Could Reverse Human Aging in Our Lifetime</i>. New York, NY: St. Martin's Press, 416 pp. <a href="/wiki/Special:BookSources/0312367066" class="internal mw-magiclink-isbn">ISBN 0-312-36706-6</a>.</span></li>
<li id="cite_note-isbn1587061554-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-isbn1587061554_3-0">^</a></b></span> <span class="reference-text">de Grey, Aubrey (November 2003). <i>The Mitochondrial Free Radical Theory of Aging.</i> Austin, Texas: Landes Bioscience. <a href="/wiki/Special:BookSources/1587061554" class="internal mw-magiclink-isbn">ISBN 1-58706-155-4</a>.</span></li>
<li id="cite_note-pmid11976218-4"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid11976218_4-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid11976218_4-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">de Grey AD, Ames BN, Andersen JK, Bartke A, Campisi J, Heward CB, McCarter RJ, Stock G (April 2002). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/pdf/manu12.pdf">Time to Talk SENS: Critiquing the Immutability of Human Aging</a>". <i>Annals of the New York Academy of Sciences</i> 959: 452–62. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/11976218?dopt=Abstract">PMID 11976218</a>.</span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text">Bulkes, Nyssa (March 6, 2006). "<a rel="nofollow" class="external text" href="http://northernstar.info/city/anti-aging-research-breakthroughs-may-add-up-to-years-to/article_a4d2acd9-475d-5e12-a81c-77011f9c65ad.html">Anti-aging research breakthroughs may add up to 25 years to life</a>". <i>The Northern Star</i>. Northern Illinois University (DeKalb, USA).</span></li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text">. "<a rel="nofollow" class="external text" href="http://www.huffingtonpost.com/aubrey-de-grey-phd/age-related-diseases_b_985019.html">Age-Related Diseases: Medicine's Final Adversary?</a>". <i>Huffington Post Healthy Living</i>.</span></li>
<li id="cite_note-PontinJuly112006-7"><span class="mw-cite-backlink">^ <a href="#cite_ref-PontinJuly112006_7-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-PontinJuly112006_7-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-PontinJuly112006_7-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-PontinJuly112006_7-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text">Pontin, Jason (July 11, 2006). "<a rel="nofollow" class="external text" href="http://www2.technologyreview.com/sens/">Is Defeating Aging Only A Dream?</a>". <i>Technology Review</i>.</span></li>
<li id="cite_note-Invincible_Man-8"><span class="mw-cite-backlink">^ <a href="#cite_ref-Invincible_Man_8-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Invincible_Man_8-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Garreau, Joel (October 31, 2007). "<a rel="nofollow" class="external text" href="http://www.washingtonpost.com/wp-dyn/content/article/2007/10/30/AR2007103002222.html?hpid=features1&amp;hpv=nationalThe">Invincible Man</a>". <i>Washington Post</i>.</span></li>
<li id="cite_note-SENS4Abstracts-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-SENS4Abstracts_9-0">^</a></b></span> <span class="reference-text">Fourth SENS Conference (2009). <a rel="nofollow" class="external text" href="http://www.sens.org/index.php?pagename=sens4_abstracts">Over 140 Accepted Abstracts</a>. Cambridge, England, September 3–7th, 2009.</span></li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text">Kristen Fortney (2009). <a rel="nofollow" class="external text" href="http://www.fightaging.org/archives/2009/09/sens4-conference-coverage-from-ouroboros.php">SENS4 Conference Coverage From Ouroboros</a>. FightAging.org, September 4, 2009.</span></li>
<li id="cite_note-EMBOSENS-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-EMBOSENS_11-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Warner H; et al. (November 2005). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1371037">"Science fact and the SENS agenda. What can we reasonably expect from ageing research?"</a>. <i>EMBO Reports</i>. <b>6</b> (11): 1006–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.embor.7400555">10.1038/sj.embor.7400555</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC1371037">1371037</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16264422">16264422</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=Science+fact+and+the+SENS+agenda.+What+can+we+reasonably+expect+from+ageing+research%3F&amp;rft.au=Anderson+J&amp;rft.au=Austad+S&amp;rft.au=Warner+H&amp;rft.date=2005-11&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1371037&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC1371037&amp;rft_id=info%3Adoi%2F10.1038%2Fsj.embor.7400555&amp;rft_id=info%3Apmid%2F16264422&amp;rft.issue=11&amp;rft.jtitle=EMBO+Reports&amp;rft.pages=1006-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=6" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-Holliday-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-Holliday_12-0">^</a></b></span> <span class="reference-text"><cite class="citation journal">Holliday R (April 2009). "The extreme arrogance of anti-aging medicine". <i>Biogerontology</i>. <b>10</b> (2): 223–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2Fs10522-008-9170-6">10.1007/s10522-008-9170-6</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/18726707">18726707</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=The+extreme+arrogance+of+anti-aging+medicine&amp;rft.au=Holliday+R&amp;rft.date=2009-04&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2Fs10522-008-9170-6&amp;rft_id=info%3Apmid%2F18726707&amp;rft.issue=2&amp;rft.jtitle=Biogerontology&amp;rft.pages=223-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=10" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid12844502-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid12844502_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid12844502_13-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">de Grey, Aubrey (January 8, 2003). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/pdf/manu16.pdf">An engineer's approach to the development of real anti-aging medicine</a>". <i>Sci Aging Knowledge Environ</i>. 2003 (1): VP1. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1126%2Fsageke.2003.1.vp1">10.1126/sageke.2003.1.vp1</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12844502?dopt=Abstract">PMID 12844502</a>.</span></li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text">de Grey, Aubrey (2005). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/FHT-PP.pdf">A strategy for postponing aging indefinitely</a>". <i>Stud Health Technol Inform.</i> 118: 209–19. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16301780?dopt=Abstract">PMID 16301780</a>.</span></li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text">de Grey AD, Campbell FC, Dokal I, Fairbairn LJ, Graham GJ, Jahoda CA, Porterg AC (June 2004). <a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/WILT.pdf">Total deletion of <i>in vivo</i> telomere elongation capacity: an ambitious but possibly ultimate cure for all age-related human cancers</a>. <i>Ann N Y Acad Sci</i>. 1019: 147–70. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1196%2Fannals.1297.026">10.1196/annals.1297.026</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15247008?dopt=Abstract">PMID 15247008</a>.</span></li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text">de Grey, Aubrey (September 1, 2005). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/WILT-FBS.pdf">Whole-body interdiction of lengthening of telomeres: a proposal for cancer prevention</a>". <i>Frontiers in Bioscience</i>. 10: 2420–29. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15970505?dopt=Abstract">PMID 15970505</a>.</span></li>
<li id="cite_note-pmid17588643-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17588643_17-0">^</a></b></span> <span class="reference-text">de Grey, Aubrey (July–August 2007). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/nucmutPP.pdf">Protagonistic pleiotropy: Why cancer may be the only pathogenic effect of accumulating nuclear mutations and epimutations in aging</a>". <i>Mech Ageing Dev</i>. 128 (7–8): 456–59. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.mad.2007.05.005">10.1016/j.mad.2007.05.005</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17588643?dopt=Abstract">PMID 17588643</a>.</span></li>
<li id="cite_note-pmid12556198-18"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid12556198_18-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid12556198_18-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid12556198_18-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text">de Grey, Aubrey (February 2003). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/manu21.pdf">Challenging but essential targets for genuine anti-ageing drugs</a>". <i>Expert Opinion on Therapeutic Targets</i>. 7 (1): 1–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1517%2F14728222.7.1.1">10.1517/14728222.7.1.1</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12556198?dopt=Abstract">PMID 12556198</a>.</span></li>
<li id="cite_note-pmid17100587-19"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid17100587_19-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid17100587_19-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid17100587_19-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text">de Grey, Aubrey (November 2006). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/excellPP.pdf">Foreseeable pharmaceutical repair of age-related extracellular damage</a>". <i>Curr Drug Targets</i>. 7 (11): 1469–77. <a href="/wiki/International_Standard_Serial_Number" title="International Standard Serial Number">ISSN</a>&#160;<a rel="nofollow" class="external text" href="//www.worldcat.org/search?fq=x0:jrnl&amp;q=n2:1389-4501">1389-4501</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/17100587?dopt=Abstract">PMID 17100587</a>.</span></li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text">de Grey, Aubrey (Fall 2004). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/polg-PP.pdf">Mitochondrial Mutations in Mammalian Aging: An Over-Hasty About-Turn?</a>" <i>Rejuvenation Res</i>. 7 (3): 171–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1089%2Frej.2004.7.171">10.1089/rej.2004.7.171</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15588517?dopt=Abstract">PMID 15588517</a>.</span></li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text">de Grey, Aubrey (September 2000). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/allo.pdf">Mitochondrial gene therapy: an arena for the biomedical use of inteins</a>". <i>Trends Biotechnol</i>. 18 (9): 394–99. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0167-7799%2800%2901476-1">10.1016/S0167-7799(00)01476-1</a>". <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/10942964?dopt=Abstract">PMID 10942964</a>.</span></li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text">de Grey, Aubrey (November 2002). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/manu15.pdf">Bioremediation meets biomedicine: therapeutic translation of microbial catabolism to the lysosome</a>". <i>Trends Biotechnol</i>. 20 (11): 452–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2FS0167-7799%2802%2902062-0">10.1016/S0167-7799(02)02062-0</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/12413818?dopt=Abstract">PMID 12413818</a>.</span></li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text">de Grey AD, Alvarez PJJ, Brady RO, Cuervo AM, Jerome WG, McCarty PL, Nixon RA, Rittmann BE, Sparrow JR (August 2005). "<a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/medbioremPP.pdf">Medical bioremediation: prospects for the application of microbial catabolic diversity to aging and several major age-related diseases</a>". <i>Ageing Research Reviews</i>. 4 (3): 315–38. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1016%2Fj.arr.2005.03.008">10.1016/j.arr.2005.03.008</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16040282?dopt=Abstract">PMID 16040282</a>.</span></li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text">Oca-Cossio, J. et al., 2003. Limitations of Allotopic Expression of Mitochondrial Genes in Mammalian Cells. Genetics, 165(2), 707-720.</span></li>
<li id="cite_note-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-25">^</a></b></span> <span class="reference-text"><cite class="citation journal">Best, BP (2009). <a rel="nofollow" class="external text" href="http://www.benbest.com/lifeext/Nuclear_DNA_in_Aging.pdf">"Nuclear DNA damage as a direct cause of aging"</a> <span style="font-size:85%;">(<a href="/wiki/PDF" class="mw-redirect" title="PDF">PDF</a>)</span>. <i>Rejuvenation Research</i>. <b>12</b> (3): 199–208. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1089%2Frej.2009.0847">10.1089/rej.2009.0847</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/19594328">19594328</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=Nuclear+DNA+damage+as+a+direct+cause+of+aging&amp;rft.au=Best%2C+BP&amp;rft.date=2009&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.benbest.com%2Flifeext%2FNuclear_DNA_in_Aging.pdf&amp;rft_id=info%3Adoi%2F10.1089%2Frej.2009.0847&amp;rft_id=info%3Apmid%2F19594328&amp;rft.issue=3&amp;rft.jtitle=Rejuvenation+Research&amp;rft.pages=199-208&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=12" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid16264422-26"><span class="mw-cite-backlink">^ <a href="#cite_ref-pmid16264422_26-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid16264422_26-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid16264422_26-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-pmid16264422_26-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text">Warner H <i>et al.</i> (November 2005). "Science fact and the SENS agenda. What can we reasonably expect from ageing research?". <i>EMBO reports</i>. 6 (11): 1006–1008. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.embor.7400555">10.1038/sj.embor.7400555</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16264422?dopt=Abstract">PMID 16264422</a>.</span></li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text">de Grey, Aubrey (July 2005). "Resistance to debate on how to postpone ageing is delaying progress and costing lives". <i>EMBO reports</i>. 6 (S1): S49–S53. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.embor.7400399">10.1038/sj.embor.7400399</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15995663?dopt=Abstract">PMID 15995663</a>.</span></li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text">de Grey, Aubrey (November 2005). "Like it or not, life-extension research extends beyond biogerontology". <i>EMBO reports</i>. 6 (11): 1000. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2Fsj.embor.7400565">10.1038/sj.embor.7400565</a>. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/16264420?dopt=Abstract">PMID 16264420</a>.</span></li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text">de Grey, Aubrey. "<a rel="nofollow" class="external text" href="http://www.mfoundation.org/files/sens/Gandhi3.htm">The biogerontology research community's evolving view of SENS</a>". Methuselah Foundation. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kyriazis M (2014). <a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4142774">"The impracticality of biomedical rejuvenation therapies: translational and pharmacological barriers"</a>. <i>Rejuvenation Research</i>. <b>17</b> (4): 390–6. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1089%2Frej.2014.1588">10.1089/rej.2014.1588</a>. <a href="/wiki/PubMed_Central" title="PubMed Central">PMC</a>&#160;<span class="plainlinks"><a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pmc/articles/PMC4142774">4142774</a><span style="margin-left:0.1em"><img alt="Freely accessible" src="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png" title="Freely accessible" width="9" height="14" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x" data-file-width="512" data-file-height="813" /></span></span>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25072550">25072550</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=The+impracticality+of+biomedical+rejuvenation+therapies%3A+translational+and+pharmacological+barriers&amp;rft.aufirst=M&amp;rft.aulast=Kyriazis&amp;rft.date=2014&amp;rft.genre=article&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4142774&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4142774&amp;rft_id=info%3Adoi%2F10.1089%2Frej.2014.1588&amp;rft_id=info%3Apmid%2F25072550&amp;rft.issue=4&amp;rft.jtitle=Rejuvenation+Research&amp;rft.pages=390-6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kyriazis, Marios (2015). "Translating laboratory anti-aging biotechnology into applied clinical practice: Problems and obstacles". <i>World Journal of Translational Medicine</i>. <b>4</b> (2): 51–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.5528%2Fwjtm.v4.i2.51">10.5528/wjtm.v4.i2.51</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=Translating+laboratory+anti-aging+biotechnology+into+applied+clinical+practice%3A+Problems+and+obstacles&amp;rft.aufirst=Marios&amp;rft.aulast=Kyriazis&amp;rft.date=2015&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.5528%2Fwjtm.v4.i2.51&amp;rft.issue=2&amp;rft.jtitle=World+Journal+of+Translational+Medicine&amp;rft.pages=51-4&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=4" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><cite class="citation journal">Kyriazis M, Apostolides A (2015). <a rel="nofollow" class="external text" href="http://www.eurekaselect.com/132663/article">"The Fallacy of the Longevity Elixir: Negligible Senescence May be Achieved, but Not by Using Something Physical"</a>. <i>Current Aging Science</i>. <b>8</b> (3): 227–34. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2174%2F1874609808666150702095803">10.2174/1874609808666150702095803</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/26135528">26135528</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=The+Fallacy+of+the+Longevity+Elixir%3A+Negligible+Senescence+May+be+Achieved%2C+but+Not+by+Using+Something+Physical&amp;rft.au=Apostolides%2C+A&amp;rft.aufirst=M&amp;rft.aulast=Kyriazis&amp;rft.date=2015&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.eurekaselect.com%2F132663%2Farticle&amp;rft_id=info%3Adoi%2F10.2174%2F1874609808666150702095803&amp;rft_id=info%3Apmid%2F26135528&amp;rft.issue=3&amp;rft.jtitle=Current+Aging+Science&amp;rft.pages=227-34&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=8" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><cite class="citation journal">de Grey AD (2014). "The practicality or otherwise of biomedical rejuvenation therapies: a response to Kyriazis". <i>Rejuvenation Research</i>. <b>17</b> (4): 397–400. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1089%2Frej.2014.1599">10.1089/rej.2014.1599</a>. <a href="/wiki/PubMed_Identifier" class="mw-redirect" title="PubMed Identifier">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/25072964">25072964</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=The+practicality+or+otherwise+of+biomedical+rejuvenation+therapies%3A+a+response+to+Kyriazis&amp;rft.aufirst=AD&amp;rft.aulast=de+Grey&amp;rft.date=2014&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1089%2Frej.2014.1599&amp;rft_id=info%3Apmid%2F25072964&amp;rft.issue=4&amp;rft.jtitle=Rejuvenation+Research&amp;rft.pages=397-400&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=17" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text">Nuland, Sherwin (1994). <i>How We Die: Reflections on Life's Final Chapter</i>. New York: Knopf Random House. <a href="/wiki/Special:BookSources/0679414614" class="internal mw-magiclink-isbn">ISBN 0-679-41461-4</a>.</span></li>
<li id="cite_note-35"><span class="mw-cite-backlink"><b><a href="#cite_ref-35">^</a></b></span> <span class="reference-text">de Grey, Aubrey (April2005). "<a rel="nofollow" class="external text" href="http://www.technologyreview.com/read_article.aspx?id=14097&amp;ch=infotech">Aubrey de Grey Responds</a>", <i>Technology Review</i>.</span></li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text">TR Readers (April 2005). "<a rel="nofollow" class="external text" href="http://www.technologyreview.com/read_article.aspx?id=14310&amp;ch=infotechReaders">LETTERS: Our February cover story on Aubrey de Grey and antiaging science lives on</a>". <i>Technology Review</i>.</span></li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text">Pontin, Jason (July 28, 2005). "<a rel="nofollow" class="external text" href="http://www.technologyreview.com/blog/pontin/14968/">The SENS Challenge</a>". <i>Technology Review</i>.</span></li>
<li id="cite_note-38"><span class="mw-cite-backlink"><b><a href="#cite_ref-38">^</a></b></span> <span class="reference-text">Pontin, Jason (March 14, 2006). "<a rel="nofollow" class="external text" href="http://www.technologyreview.com/Biotech/16593/">We've picked the judges for our biogerontology prize</a>". <i>Technology Review</i>.</span></li>
<li id="cite_note-39"><span class="mw-cite-backlink"><b><a href="#cite_ref-39">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="https://web.archive.org/web/20130606111748/http://www.mprize.com/index.php?pagename=newsdetaildisplay&amp;ID=0104">SENS Withstands Three Challenges&#160;: $20,000 Remains Unclaimed</a>". Methuselah Foundation. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-doi10.2202.2F1941-6008.1011-40"><span class="mw-cite-backlink">^ <a href="#cite_ref-doi10.2202.2F1941-6008.1011_40-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-doi10.2202.2F1941-6008.1011_40-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal"><a href="/wiki/Aubrey_de_Grey" title="Aubrey de Grey">Aubrey D.N.J, de Grey</a> (2007). <a rel="nofollow" class="external text" href="http://www.sens.org/files/sens/ENHANCE-PP.pdf">"Life Span Extension Research and Public Debate: Societal Considerations"</a> <span style="font-size:85%;">(PDF)</span>. <i>Studies in Ethics, Law, and Technology</i>. <b>1</b> (1, Article 5). <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.2202%2F1941-6008.1011">10.2202/1941-6008.1011</a><span class="reference-accessdate">. Retrieved <span class="nowrap">March 20,</span> 2009</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=Life+Span+Extension+Research+and+Public+Debate%3A+Societal+Considerations&amp;rft.aufirst=de+Grey&amp;rft.aulast=Aubrey+D.N.J&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=http%3A%2F%2Fwww.sens.org%2Ffiles%2Fsens%2FENHANCE-PP.pdf&amp;rft_id=info%3Adoi%2F10.2202%2F1941-6008.1011&amp;rft.issue=1%2C+Article+5&amp;rft.jtitle=Studies+in+Ethics%2C+Law%2C+and+Technology&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=1" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-TheLongevityDividend-41"><span class="mw-cite-backlink">^ <a href="#cite_ref-TheLongevityDividend_41-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-TheLongevityDividend_41-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Olshansky, S. Jay; Perry, Daniel; Miller, Richard A.; Butler, Robert N. (March 2006). "<a rel="nofollow" class="external text" href="https://web.archive.org/web/20160110004616/http://www.edmontonagingsymposium.com/files/eas/Longevity_Dividend.pdf">In Pursuit of the Longevity Dividend: What Should We Be Doing To Prepare for the Unprecedented Aging of Humanity?</a>". <i>The Scientist</i>. 20 (3): 28–36.</span></li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="https://web.archive.org/web/20081021070535/http://www.mprize.com/index.php?pagename=meetings">Conferences</a>". Methuselah Foundation. Retrieved on July 17, 2008.</span></li>
<li id="cite_note-sens6-43"><span class="mw-cite-backlink">^ <a href="#cite_ref-sens6_43-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-sens6_43-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.sens.org/outreach/conferences/sens6">"Sixth SENS Conference (SENS6)"</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.btitle=Sixth+SENS+Conference+%28SENS6%29&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.sens.org%2Foutreach%2Fconferences%2Fsens6&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="https://web.archive.org/web/20080827212037/http://www.methuselahfoundation.org/files/sens/SENS1.htm">SENS roundtable 1: Biotechnological foreseeability of ENS (October 1, 2000)</a>". Methuselah Foundation. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="https://web.archive.org/web/20080523163019/http://www.mfoundation.org/meetings/roundtable4">SENS roundtable 4: Enhancing lysosomal catabolic function using microbial enzymes (July 26, 2004)</a>". Methuselah Foundation. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="https://web.archive.org/web/20160216041842/http://edmontonagingsymposium.com/index.php?pagename=eas_program">Program</a>". Edmonton Aging Symposium. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="https://web.archive.org/web/20160603084755/http://www.edmontonagingsymposium.com/index.php?pagename=eas_archive">Presentation Archive</a>". Edmonton Aging Symposium. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20090225054539/http://mfoundation.org/UABBA/">"Understanding Aging"</a>. Methuselah Foundation. 2008. Archived from <a rel="nofollow" class="external text" href="http://www.mfoundation.org/UABBA/">the original</a> on February 25, 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-03-02</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.btitle=Understanding+Aging&amp;rft.date=2008&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.mfoundation.org%2FUABBA%2F&amp;rft.pub=Methuselah+Foundation&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="http://www.methuselahfoundation.org/files/iabg10/">The International Association of Biomedical Gerontology 10th Congress (September 19–23, 2003)</a>". Methuselah Foundation. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text">de Grey, Aubrey, Ed. (June 2004). "Strategies for Engineered Negligible Senescence: Why Genuine Control of Aging May Be Foreseeable". <i>Annals of the New York Academy of Sciences</i>. 1019: xv–xvi; 1–592. <a class="external mw-magiclink-pmid" rel="nofollow" href="//www.ncbi.nlm.nih.gov/pubmed/15320311?dopt=Abstract">PMID 15320311</a>.</span></li>
<li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="http://www.mfoundation.org/files/sens2/">Strategies for Engineered Negligible Senescence (SENS), Second Conference (September 7–11, 2005)</a>". Methuselah Foundation. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="http://www.mfoundation.org/files/sens3/">Strategies for Engineered Negligible Senescence (SENS), Third Conference (September 6–10, 2007)</a>". Methuselah Foundation. Retrieved on July 1, 2008.</span></li>
<li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mfoundation.org/sens4">"Strategies for Engineered Negligible Senescence (SENS), Fourth Conference"</a>. <i>SENS4 — Cambridge</i>. Methuselah Foundation. 2008<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-03-02</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=Strategies+for+Engineered+Negligible+Senescence+%28SENS%29%2C+Fourth+Conference&amp;rft.date=2008&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fwww.mfoundation.org%2Fsens4&amp;rft.jtitle=SENS4+%94+Cambridge&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://ouroboros.wordpress.com/2009/09/03/sens4-coverage/">"Strategies for Engineered Negligible Senescence: Covering the SENS4 conference"</a>. <i>Research in the biology of aging</i>. Ouroboros. September 3, 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">2009-09-09</span></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AStrategies+for+Engineered+Negligible+Senescence&amp;rft.atitle=Strategies+for+Engineered+Negligible+Senescence%3A+Covering+the+SENS4+conference&amp;rft.date=2009-09-03&amp;rft.genre=unknown&amp;rft_id=http%3A%2F%2Fouroboros.wordpress.com%2F2009%2F09%2F03%2Fsens4-coverage%2F&amp;rft.jtitle=Research+in+the+biology+of+aging&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-MFMission-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-MFMission_55-0">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="https://web.archive.org/web/20080725074128/http://www.mprize.org/index.php?pagename=mission">What is the Methuselah Foundation?</a>". Methuselah Foundation. Retrieved on July 5, 2008.</span></li>
<li id="cite_note-56"><span class="mw-cite-backlink"><b><a href="#cite_ref-56">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://nextbigfuture.com/2013/07/aubrey-de-grey-donates-13-million-of.html">Aubrey de Grey</a> donates $13 million of his own wealth to SENS life extension</span></li>
<li id="cite_note-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-57">^</a></b></span> <span class="reference-text">Internet Entrepreneur <a rel="nofollow" class="external text" href="http://jasonhope.com/press/61-sens-foundation">Jason Hope</a> Pledges A Donation To SENS Foundation</span></li>
</ol>
</div>
<h3><span class="mw-headline" id="Bibliography">Bibliography</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit&amp;section=18" title="Edit section: Bibliography">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<ul>
<li>de Grey, Aubrey; Rae, Michael (September 2007). <i><a href="/wiki/Ending_Aging" title="Ending Aging">Ending Aging: The Rejuvenation Breakthroughs that Could Reverse Human Aging in Our Lifetime</a></i>. New York, NY: St. Martin's Press, 416 pp.&#160;<a href="/wiki/Special:BookSources/0312367066" class="internal mw-magiclink-isbn">ISBN 0-312-36706-6</a>.</li>
</ul>
<div role="navigation" class="navbox" aria-labelledby="Outline_of_life_extension" style="padding:3px">
<table class="nowraplinks collapsible collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="3" style="background:#F0FFFF">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Life_extension" title="Template:Life extension"><abbr title="View this template" style=";background:#F0FFFF;background:none transparent;border:none;">v</abbr></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Life_extension" title="Template talk:Life extension"><abbr title="Discuss this template" style=";background:#F0FFFF;background:none transparent;border:none;">t</abbr></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Life_extension&amp;action=edit"><abbr title="Edit this template" style=";background:#F0FFFF;background:none transparent;border:none;">e</abbr></a></li>
</ul>
</div>
<div id="Outline_of_life_extension" style="font-size:114%"><a href="/wiki/Outline_of_life_extension" title="Outline of life extension">Outline of</a> <a href="/wiki/Life_extension" title="Life extension">life extension</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:#F0FFFF">Issues</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Antioxidant" title="Antioxidant">Anti-oxidants</a></li>
<li><a href="/wiki/Anti-aging_movement" title="Anti-aging movement">Anti-aging movement</a></li>
<li><a href="/wiki/Grinder_(biohacking_community)" class="mw-redirect" title="Grinder (biohacking community)">Biohacking</a></li>
<li><a href="/wiki/Calorie_restriction" title="Calorie restriction">Calorie restriction</a></li>
<li><a href="/wiki/Chemical_brain_preservation" title="Chemical brain preservation">Chemical brain preservation</a></li>
<li><a href="/wiki/Cryonics" title="Cryonics">Cryonics</a></li>
<li><a href="/wiki/Cyborg" title="Cyborg">Cyborg</a></li>
<li><a href="/wiki/Physical_exercise" title="Physical exercise">Exercise</a></li>
<li><a href="/wiki/Free-radical_theory" class="mw-redirect" title="Free-radical theory">Free-radical theory</a></li>
<li><a href="/wiki/Gene_therapy" title="Gene therapy">Gene therapy</a></li>
<li><a href="/wiki/Gerontology" title="Gerontology">Gerontology</a></li>
<li><a href="/wiki/Glycation" title="Glycation">Glycation</a></li>
<li><a href="/wiki/Indefinite_lifespan" title="Indefinite lifespan">Indefinite lifespan</a></li>
<li><a href="/wiki/Index_of_topics_related_to_life_extension" title="Index of topics related to life extension">Index of topics related to life extension</a></li>
<li><a href="/wiki/List_of_aging_processes" title="List of aging processes">List of aging processes</a></li>
<li><a href="/wiki/Longevity_escape_velocity" title="Longevity escape velocity">Longevity escape velocity</a></li>
<li><a href="/wiki/Mind_uploading" title="Mind uploading">Mind uploading</a></li>
<li><a href="/wiki/Nanomedicine" title="Nanomedicine">Nanomedicine</a></li>
<li><a href="/wiki/Organ_printing" title="Organ printing">Organ printing</a></li>
<li><a href="/wiki/Rejuvenation_(aging)" title="Rejuvenation (aging)">Rejuvenation</a></li>
<li><a href="/wiki/Senescence" title="Senescence">Senescence</a></li>
<li><a href="/wiki/Stem-cell_therapy" title="Stem-cell therapy">Stem-cell therapy</a></li>
<li><strong class="selflink">Strategies for Engineered Negligible Senescence</strong></li>
<li><a href="/wiki/Transhumanist_politics" title="Transhumanist politics">Transhumanist politics</a></li>
</ul>
</div>
</td>
<td class="navbox-image" rowspan="9" style="width:0%;padding:0px 0px 0px 2px">
<div><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/5/58/Infinity_in_circle.svg/120px-Infinity_in_circle.svg.png" width="120" height="120" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/5/58/Infinity_in_circle.svg/180px-Infinity_in_circle.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/5/58/Infinity_in_circle.svg/240px-Infinity_in_circle.svg.png 2x" data-file-width="155" data-file-height="155" /></div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:#F0FFFF">People</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/William_H._Andrews_(biologist)" title="William H. Andrews (biologist)">Bill Andrews</a></li>
<li><a href="/wiki/Eric_R._Braverman" title="Eric R. Braverman">Eric R. Braverman</a></li>
<li><a href="/wiki/Aubrey_de_Grey" title="Aubrey de Grey">Aubrey de Grey</a></li>
<li><a href="/wiki/Laura_Deming" title="Laura Deming">Laura Deming</a></li>
<li><a href="/wiki/Denham_Harman" title="Denham Harman">Denham Harman</a></li>
<li><a href="/wiki/Leonard_Hayflick" title="Leonard Hayflick">Leonard Hayflick</a></li>
<li><a href="/wiki/Saul_Kent" title="Saul Kent">Saul Kent</a></li>
<li><a href="/wiki/Cynthia_Kenyon" title="Cynthia Kenyon">Cynthia Kenyon</a></li>
<li><a href="/wiki/Ray_Kurzweil" title="Ray Kurzweil">Ray Kurzweil</a></li>
<li><a href="/wiki/Marios_Kyriazis" title="Marios Kyriazis">Marios Kyriazis</a></li>
<li><a href="/wiki/Liz_Parrish" class="mw-redirect" title="Liz Parrish">Liz Parrish</a></li>
<li><a href="/wiki/Durk_Pearson" title="Durk Pearson">Durk Pearson</a></li>
<li><a href="/wiki/Mark_Roth_(scientist)" title="Mark Roth (scientist)">Mark Roth</a></li>
<li><a href="/wiki/Sandy_Shaw" title="Sandy Shaw">Sandy Shaw</a></li>
<li><a href="/wiki/Roy_Walford" title="Roy Walford">Roy Walford</a></li>
<li><a href="/wiki/Michael_D._West" title="Michael D. West">Michael D. West</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:#F0FFFF">Organizations</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/2045_Initiative" title="2045 Initiative">2045 Initiative</a></li>
<li><a href="/wiki/Alliance_for_Aging_Research" title="Alliance for Aging Research">Alliance for Aging Research</a></li>
<li><a href="/wiki/American_Academy_of_Anti-Aging_Medicine" title="American Academy of Anti-Aging Medicine">American Academy of Anti-Aging Medicine</a></li>
<li><a href="/wiki/American_Aging_Association" title="American Aging Association">American Aging Association</a></li>
<li><a href="/wiki/Buck_Institute_for_Research_on_Aging" title="Buck Institute for Research on Aging">Buck Institute for Research on Aging</a></li>
<li><a href="/wiki/BioViva" title="BioViva">BioViva</a></li>
<li><a href="/wiki/Calico_(company)" title="Calico (company)">Calico</a></li>
<li><a href="/wiki/Life_Extension_Foundation" title="Life Extension Foundation">Life Extension Foundation</a></li>
<li><a href="/wiki/Methuselah_Foundation" title="Methuselah Foundation">Methuselah Foundation</a></li>
<li><a href="/wiki/SENS_Research_Foundation" title="SENS Research Foundation">SENS Research Foundation</a></li>
<li><a href="/wiki/Sierra_Sciences" title="Sierra Sciences">Sierra Sciences</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:#F0FFFF">Books</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><i><a href="/wiki/Life_Extension:_A_Practical_Scientific_Approach" title="Life Extension: A Practical Scientific Approach">Life Extension</a></i> (1982)</li>
<li><i><a href="/wiki/The_10%25_Solution_for_a_Healthy_Life" title="The 10% Solution for a Healthy Life">The 10% Solution for a Healthy Life</a></i> (1993)</li>
<li><i><a href="/wiki/The_First_Immortal" title="The First Immortal">The First Immortal</a></i> (1998)</li>
<li><i><a href="/wiki/Fantastic_Voyage:_Live_Long_Enough_to_Live_Forever" title="Fantastic Voyage: Live Long Enough to Live Forever">Fantastic Voyage</a></i> (2004)</li>
<li><i><a href="/wiki/Ending_Aging" title="Ending Aging">Ending Aging</a></i> (2007)</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group" style="background:#F0FFFF">Categories</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Category:Life_extension" title="Category:Life extension">Life extension</a></li>
</ul>
</div>
</td>
</tr>
</table>
</div>


<!-- 
NewPP limit report
Parsed by mw1219
Cached time: 20161205035546
Cache expiry: 2592000
Dynamic content: false
CPU time usage: 0.268 seconds
Real time usage: 0.341 seconds
Preprocessor visited node count: 2147/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 51083/2097152 bytes
Template argument size: 5441/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 2/500
Lua time usage: 0.089/10.000 seconds
Lua memory usage: 4.51 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00%  258.428      1 - -total
 52.44%  135.515      1 - Template:Reflist
 22.01%   56.882      8 - Template:Cite_journal
 21.23%   54.858      1 - Template:Cn
 15.96%   41.255      1 - Template:Fix
 11.23%   29.030      4 - Template:Category_handler
  6.91%   17.859      1 - Template:Clarify
  6.87%   17.755      2 - Template:Delink
  6.07%   15.692      1 - Template:Fix-span
  5.39%   13.935      4 - Template:Cite_web
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:1364342-0!*!0!!en!4!* and timestamp 20161205035545 and revision id 739665012
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;oldid=739665012">https://en.wikipedia.org/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;oldid=739665012</a>"					</div>
				<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:1999_introductions" title="Category:1999 introductions">1999 introductions</a></li><li><a href="/wiki/Category:Ageing" title="Category:Ageing">Ageing</a></li><li><a href="/wiki/Category:Immortality" title="Category:Immortality">Immortality</a></li><li><a href="/wiki/Category:Regenerative_biomedicine" title="Category:Regenerative biomedicine">Regenerative biomedicine</a></li><li><a href="/wiki/Category:Biomedical_engineering" title="Category:Biomedical engineering">Biomedical engineering</a></li><li><a href="/wiki/Category:Emerging_technologies" title="Category:Emerging technologies">Emerging technologies</a></li><li><a href="/wiki/Category:Gerontology" title="Category:Gerontology">Gerontology</a></li><li><a href="/wiki/Category:Life_extension" title="Category:Life extension">Life extension</a></li><li><a href="/wiki/Category:Gene_therapy" title="Category:Gene therapy">Gene therapy</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">CS1 maint: Explicit use of et al.</a></li><li><a href="/wiki/Category:Pages_using_ISBN_magic_links" title="Category:Pages using ISBN magic links">Pages using ISBN magic links</a></li><li><a href="/wiki/Category:Pages_using_PMID_magic_links" title="Category:Pages using PMID magic links">Pages using PMID magic links</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_September_2016" title="Category:Articles with unsourced statements from September 2016">Articles with unsourced statements from September 2016</a></li><li><a href="/wiki/Category:Wikipedia_articles_needing_clarification_from_April_2016" title="Category:Wikipedia articles needing clarification from April 2016">Wikipedia articles needing clarification from April 2016</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-anonuserpage">Not logged in</li><li id="pt-anontalk"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n">Talk</a></li><li id="pt-anoncontribs"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y">Contributions</a></li><li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Strategies+for+Engineered+Negligible+Senescence" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Strategies+for+Engineered+Negligible+Senescence" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Strategies_for_Engineered_Negligible_Senescence"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Strategies_for_Engineered_Negligible_Senescence"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Strategies_for_Engineered_Negligible_Senescence" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=history"  title="Past revisions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search Wikipedia" title="Search Wikipedia [f]" accesskey="f" id="searchInput"/><input type="hidden" value="Special:Search" name="title"/><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton"/><input type="submit" name="go" value="Go" title="Go to a page with this exact name if it exists" id="searchButton" class="searchButton"/>							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikipedia store">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Strategies_for_Engineered_Negligible_Senescence" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Strategies_for_Engineered_Negligible_Senescence" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;oldid=739665012" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="https://www.wikidata.org/wiki/Q523483" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Strategies_for_Engineered_Negligible_Senescence&amp;id=739665012" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Strategies+for+Engineered+Negligible+Senescence">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Strategies+for+Engineered+Negligible+Senescence&amp;returnto=Strategies+for+Engineered+Negligible+Senescence&amp;oldid=739665012&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-de"><a href="https://de.wikipedia.org/wiki/Strategies_for_Engineered_Negligible_Senescence" title="Strategies for Engineered Negligible Senescence – German" lang="de" hreflang="de" class="interlanguage-link-target">Deutsch</a></li><li class="interlanguage-link interwiki-fr"><a href="https://fr.wikipedia.org/wiki/Strategies_for_Engineered_Negligible_Senescence" title="Strategies for Engineered Negligible Senescence – French" lang="fr" hreflang="fr" class="interlanguage-link-target">Français</a></li><li class="interlanguage-link interwiki-pt"><a href="https://pt.wikipedia.org/wiki/Strategies_for_Engineered_Negligible_Senescence" title="Strategies for Engineered Negligible Senescence – Portuguese" lang="pt" hreflang="pt" class="interlanguage-link-target">Português</a></li><li class="interlanguage-link interwiki-zh"><a href="https://zh.wikipedia.org/wiki/%E6%8E%8C%E6%8E%A7%E5%8F%AF%E5%BF%BD%E7%95%A5%E8%A1%B0%E8%80%81" title="掌控可忽略衰老 – Chinese" lang="zh" hreflang="zh" class="interlanguage-link-target">中文</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Q523483#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 16 September 2016, at 04:55.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="https://wikimediafoundation.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-cookiestatement"><a href="https://wikimediafoundation.org/wiki/Cookie_statement">Cookie statement</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Strategies_for_Engineered_Negligible_Senescence&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="https://wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="/static/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/static/images/poweredby_mediawiki_132x47.png 1.5x, /static/images/poweredby_mediawiki_176x62.png 2x" width="88" height="31"/></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>(window.RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":70,"wgHostname":"mw1261"});});</script>
	</body>
</html>
